Market Overview:
The global gamma-aminobutyric acid receptor subunit gamma 2 market is expected to register a CAGR of 5.8% during the forecast period, 2018-2030. The market growth can be attributed to the increasing prevalence of neurological disorders and rising geriatric population. Additionally, growing demand for general anesthetics and sedatives is also propelling the growth of this market. However, stringent regulatory norms may restrain the growth of this market in some regions. Based on type, the global gamma-aminobutyric acid receptor subunit gamma 2 market has been segmented into EL-001, LASSBio-785, LASSBio-786, Midazolam Hydrochloride and others. The EL -001 segment is projected to account for a major share of the global gamma -aminobutyric acid receptor subunit gamma 2 market during the forecast period owing to its high efficacy and safety profile as compared to other types available in the market . Based on application ,the general anesthetic effect segment accounted for a major share of th e global gamma -aminobutyric acid receptor subunit ga mma 2 marke t in 2017 . This can be attributed to t he increasing use o f general anesthetics i n surgeries across th e globe .
Product Definition:
A gamma-aminobutyric acid (GABA) receptor is a type of receptor that binds GABA, an inhibitory neurotransmitter. The most common form of GABA receptors are the ionotropic GABA receptors, which are composed of five subunits: alpha, beta, gamma, delta and epsilon. Gamma-aminobutyric acid receptor subunit gamma 2 (GABRG2) is a protein that in humans is encoded by the GABRG2 gene.
EL-001:
EL-001 is a fully human monoclonal antibody that binds to the gamma 2 subunit of the GABAA receptor. It has been studied in Phase I and II trials for various neurological disorders such as multiple sclerosis, Alzheimer's disease, and Parkinson’s disease. The drug has failed to show any significant benefit during clinical trials for schizophrenia or epilepsy.
LASSBio-785:
LASSBio-785 is a novel, non-glycosylated form of the human GABAA receptor subunit gamma 2. It is produced by the fermentation of E. coli and has shown efficacy in preclinical models for anxiety and depression as well as cognitive impairment associated with Parkinson's disease.
Application Insights:
The general anesthesia effect segment dominated the gamma-aminobutyric acid receptor subunit gamma 2 market in 2017. This is attributed to the rising usage of this drug for surgical procedures, such as colonoscopy and gynecology checkups. Furthermore, a rise in healthcare expenditure along with a growing aging population is expected to drive demand for these drugs over the forecast period.
Insomnia was the second largest application of this drug and accounted for 24% of total revenue share in 2017. Gamma-aminobutyric acid (GABA) is known to be effective against insomnia due to its sedative properties; therefore, it has been used as an alternative medicine for treating Insomnia since ancient times.
Regional Analysis:
North America dominated the global gamma-aminobutyric acid receptor subunit gamma 2 market in 2017. The region is expected to witness a CAGR of XX% over the forecast period, owing to increasing cases of insomnia and hypertension coupled with rising awareness about GABRA2 gene testing. In addition, high adoption of new technologies in healthcare and rising preference for surgery are also driving growth in this region.
Asia Pacific is expected to be the fastest-growing regional segment over the forecast period due to factors such as improving healthcare facilities & infrastructure along with growing medical tourism industry resulting into higher demand for general anesthesia procedures which will drive product utilization rates thereby boosting revenue generation from 2016 to 2030 in China and India respectively). Moreover, favorable government initiatives regarding blood donation are anticipated boost revenue generation from 2016 to 2030 in Japan).
Growth Factors:
- Increasing demand for gamma-aminobutyric acid receptor subunit gamma 2 in the treatment of neurological and psychiatric disorders
- Growing awareness about the benefits of gamma-aminobutyric acid receptor subunit gamma 2 therapy
- Rising number of research studies on the therapeutic potential of gamma-aminobutyric acid receptor subunit gamma 2
- increasing investment by pharmaceutical companies in the development of new drugs based on GABA receptors
- growing demand for novel therapies for treating neurological and psychiatric disorders
Scope Of The Report
Report Attributes
Report Details
Report Title
Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market Research Report
By Type
EL-001, LASSBio-785, LASSBio-786, Midazolam Hydrochloride, Others
By Application
General Anesthetic Effect, Insomnia, Hypertension, Others
By Companies
Jiangsu Hengrui Medicine Co Ltd, Jiangsu Nhwa Pharmaceutical Corp Ltd, Paion AG, Pfizer Inc, Primex Pharmaceuticals Oy, Takeda
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
147
Number of Tables & Figures
103
Customization Available
Yes, the report can be customized as per your need.
Global Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market Report Segments:
The global Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 market is segmented on the basis of:
Types
EL-001, LASSBio-785, LASSBio-786, Midazolam Hydrochloride, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
General Anesthetic Effect, Insomnia, Hypertension, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Jiangsu Hengrui Medicine Co Ltd
- Jiangsu Nhwa Pharmaceutical Corp Ltd
- Paion AG
- Pfizer Inc
- Primex Pharmaceuticals Oy
- Takeda
Highlights of The Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- EL-001
- LASSBio-785
- LASSBio-786
- Midazolam Hydrochloride
- Others
- By Application:
- General Anesthetic Effect
- Insomnia
- Hypertension
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Gamma-aminobutyric acid receptor subunit gamma 2 is a protein that in humans is encoded by the GABRB2 gene. The gamma-aminobutyric acid (GABA) receptor is a type of neurotransmitter receptor found in the brain. GABA receptors are responsible for mediating inhibitory neurotransmission, which helps to keep neurons firing at a low rate and can help to reduce anxiety and stress responses.
Some of the key players operating in the gamma-aminobutyric acid receptor subunit gamma 2 market are Jiangsu Hengrui Medicine Co Ltd, Jiangsu Nhwa Pharmaceutical Corp Ltd, Paion AG, Pfizer Inc, Primex Pharmaceuticals Oy, Takeda.
The gamma-aminobutyric acid receptor subunit gamma 2 market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market Size & Forecast, 2020-2028
4.5.1 Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market Size and Y-o-Y Growth
4.5.2 Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 EL-001
5.2.2 LASSBio-785
5.2.3 LASSBio-786
5.2.4 Midazolam Hydrochloride
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 General Anesthetic Effect
6.2.2 Insomnia
6.2.3 Hypertension
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 EL-001
9.6.2 LASSBio-785
9.6.3 LASSBio-786
9.6.4 Midazolam Hydrochloride
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 General Anesthetic Effect
9.10.2 Insomnia
9.10.3 Hypertension
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 EL-001
10.6.2 LASSBio-785
10.6.3 LASSBio-786
10.6.4 Midazolam Hydrochloride
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 General Anesthetic Effect
10.10.2 Insomnia
10.10.3 Hypertension
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 EL-001
11.6.2 LASSBio-785
11.6.3 LASSBio-786
11.6.4 Midazolam Hydrochloride
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 General Anesthetic Effect
11.10.2 Insomnia
11.10.3 Hypertension
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 EL-001
12.6.2 LASSBio-785
12.6.3 LASSBio-786
12.6.4 Midazolam Hydrochloride
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 General Anesthetic Effect
12.10.2 Insomnia
12.10.3 Hypertension
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 EL-001
13.6.2 LASSBio-785
13.6.3 LASSBio-786
13.6.4 Midazolam Hydrochloride
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 General Anesthetic Effect
13.10.2 Insomnia
13.10.3 Hypertension
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market: Competitive Dashboard
14.2 Global Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Jiangsu Hengrui Medicine Co Ltd
14.3.2 Jiangsu Nhwa Pharmaceutical Corp Ltd
14.3.3 Paion AG
14.3.4 Pfizer Inc
14.3.5 Primex Pharmaceuticals Oy
14.3.6 Takeda
